# Managing Acute Severe Ulcerative Colitis in 2025 and Beyond

## TL;DR

This paper reviews current and future strategies for managing acute severe ulcerative colitis to improve outcomes and reduce colectomy rates.

## Contribution

The paper highlights novel biomarkers, predictive models, and emerging therapies for personalized ASUC management.

## Key findings

- Novel biomarkers and predictive models help identify high-risk ASUC patients for colectomy.
- Janus kinase inhibitors show promise in reducing colectomy rates but require more evidence.
- Personalized therapy selection and real-time prognostic tools are emphasized for better treatment outcomes.

## Abstract

Acute severe ulcerative colitis (ASUC) remains a high-risk condition with suboptimal clinical outcomes despite advancements in diagnostics, prognostication, and therapies. This review synthesizes recent evidence to address critical gaps in care, focusing on optimizing medical strategies to reduce colectomy rates and improve patient outcomes.

Recent studies have identified novel biomarkers and predictive models for stratifying patients as high-risk for colectomy. Several emerging therapeutic strategies to optimize care have also been explored. Intensified infliximab dosing has not consistently shown improved clinical outcomes across all patients with ASUC, though it may benefit a subset of patients with unfavorable pharmacokinetics. Furthermore, Janus kinase inhibitors have shown promise in reducing colectomy rates, offering a potential alternative for select patients; however, supporting evidence remains preliminary. Despite these advancements, colectomy remains exceedingly common but continues to serve as a critical intervention to reduce complications and mortality. This underscores the therapeutic efficacy ceiling that still exists in our current approach to ASUC in 2025.

Modern ASUC management prioritizes rapid risk stratification (using clinical, endoscopic, and biomarker data) and patient-tailored advanced therapy selection. Future strategies should focus on conducting rigorous trials of emerging agents in comparison to our current protocols, while integrating real-time, personalized, and dynamic prognostic tools to reduce heterogeneity in treatment response.